Match!
Chris M. Kozma
University of South Carolina
Health careIntensive care medicinePhysical therapyMultiple sclerosisMedicine
126Publications
19H-index
1,586Citations
What is this?
Publications 126
Newest
Source
#1Erik MuserH-Index: 11
#2Camilo ObandoH-Index: 2
Last. Chris M. KozmaH-Index: 19
view all 5 authors...
Source
#1Camilo ObandoH-Index: 2
#2Zhijie DingH-Index: 1
Last. Chris M. KozmaH-Index: 19
view all 5 authors...
Source
#1Camilo ObandoH-Index: 2
#2Zhijie DingH-Index: 1
Last. Chris M. KozmaH-Index: 19
view all 5 authors...
Source
#1Adam D. Porath (Renown Health)
#2Sharon Clodfelter (Renown Health)
Last. Michael J. BlochH-Index: 11
view all 7 authors...
Abstract Purpose Renown Health (Reno, Nevada), a large, locally owned, not-for-profit integrated health care network, has developed an institution-wide policy to shift the treatment of deep vein thrombosis (DVT) from a short-acting anticoagulant and vitamin K antagonist to the direct oral anticoagulant rivaroxaban combined with pharmacy-directed follow-up at an outpatient anticoagulation clinic. We examined data on hospitalizations and costs pre–/post–policy change. Methods Data were obtained fr...
Source
#1James D. BowenH-Index: 58
#2Chris M. KozmaH-Index: 19
Last. Amy L. Phillips (Merck Serono)H-Index: 10
view all 4 authors...
BackgroundAdministrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings.ObjectiveTo evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide).MethodsPatients from an administrative claims database (1 Jan 2012–31 Dec 2015) were selected if they: were 18–63...
1 CitationsSource
#1Fulton F. VelezH-Index: 1
Last. Ramy A. MahmoudH-Index: 27
view all 6 authors...
Source
#1Camilo ObandoH-Index: 2
Last. Chris M. KozmaH-Index: 19
view all 7 authors...
Source
#1Amy Perrin-Ross (LUC: Loyola University Chicago)
#2Chris M. KozmaH-Index: 19
Last. Amy L. Phillips (Merck Serono)H-Index: 10
view all 4 authors...
Objective: To evaluate the propensity for being highly adherent to subcutaneous interferon beta-1a (scIFNβ1a) versus dimethyl fumarate in patients with multiple sclerosis (MS). Background: Adherence to prescribed disease-modifying drug (DMD) treatment regimens is important for the optimization of patient care in MS. Design/Methods: Data from patients with MS were obtained from the US National Health and Wellness Survey or Lightspeed Research panel and its affiliates (eligible patients completed ...
Source
12345678910